Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 350 participants.

Also called NCT05763875

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 350 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05763875
Other papers using this trial's data
  • Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial Journal of the American College of Cardiology, 2025-07-22 DOI, PubMed 40392667

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Colombia, Germany, Hungary, Mexico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05763875. Randomized; triple masking; primary purpose treatment. Start 2023-03-15 (actual); primary completion 2024-06-20 (actual). Results posted on 2025-08-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.
Acronym
V-Mono
Condition
Hypercholesterolemia
Intervention (Drug)
Inclisiran
Intervention (Drug)
Ezetimibe
Intervention (Drug)
Matching Placebo for Inclisiran
Intervention (Drug)
Matching Placebo for Ezetimibe
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05763875
Content hash
2a97abfadc2530a4bb2eae7e61eed962dafe3ce0e434ebe42d4abb0c5c162744